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SUMMARY Apoptosis is a process of programmed cell death that 
maintains homeostasis of the skin. Apoptotic cell death regulates 
keratinocyte proliferation and formation of stratum corneum. The 
process by which keratinocytes undergo apoptosis is a multistep 
program mediated by binding of specific death ligands to death 
receptors or by the release of effector cell granules. Dysfunctional 
apoptosis has an important role in the development of several skin 
diseases. Psoriasis is a common chronic inflammatory skin disease 
characterized by hyperproliferation with incomplete differentiation 
of epidermal keratinocytes and decreased keratinocyte apoptosis. 
Psoriatic keratinocytes possess an enhanced ability to resist 
apoptosis, which might be one of the key pathogenetic mechanisms 
in psoriasis. In addition, psoriasis is nowadays also recognized as 
the most prevalent autoimmune disease resulting from aberrant 
activation of both innate and adaptive immunity. However, the role 
of cell cytotoxicity mediated by cytotoxic CD8+ T cells and NK cells 
in psoriasis is as yet unclear. Here, we review the role of different 
apoptotic pathways in psoriasis.
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IntRODUCtIOn
 Apoptosis is a unique process of programmed 
cell death that maintains homeostasis of the skin. 
Kerr et al. were the first to describe apoptosis as 
an active process morphologically characterized 
by cell shrinkage, nuclear condensation, cellular 
fragmentation and phagocytosis by neighboring 
macrophages and dendritic cells (1). Apoptosis 
plays a critical role in several physiologic func-
tions such as cell deletion during embryonic de-
velopment, balancing cell number in continuously 
renewing tissues, and immune system develop-
ment (2). In the skin, apoptotic cell death regulates 
keratinocyte proliferation and formation of stratum 
corneum. Balance between cell death and cell 
proliferation maintains homeostasis of epidermal 
compartment (3). The gradients of antiapoptotic 
and apoptotic factors control the timing of apop-
tosis in the epidermis, thus regulating epidermal 
growth and differentiation. It seems that terminal 
differentiation of keratinocytes represents simply 
a special form of apoptosis (4). 
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 Apoptotic pathways relevant in keratinocyte 
apoptosis include several mechanisms. The “ex-
trinsic” pathway is triggered by binding of Fas li-
gand (FasL) or tumor necrosis factor (TNF) to 
membrane death receptors that recruit adapter 
molecules leading to the activation of caspase-8 
(2,5). The “intrinsic” pathway includes mitochon-
drial release of cytochrome c and along with the 
cofactor Apaf-1, the formation of an activated cas-
pase-9 apoptosome (2,6). Mitochondria might also 
trigger apoptosis through the release of Smac/
DIABLO blocking inhibitor of apoptosis (IAP) or 
by apoptosis-inducing factor (AIF) that mediates 
caspase-independent apoptosis (2). Finally, both 
pathways end in DNA cleavage followed by the 
formation of apoptotic bodies and phagocytosis by 
neighboring cells. Apoptosis is controlled by Bcl-2 
family proteins of which some (Bcl-2, Bcl-xL) may 
block apoptosis, whereas others (Bax, bak, Bid) 
stimulate apoptotic process (7). 
 Dysfunctional apoptosis has an important role 
in the development of several skin diseases (2,8). 
Some are characterized by increased keratino-
cyte apoptosis, e.g., toxic epidermal necrolysis 
or graft-versus-host disease, whereas others like 
non-melanoma skin cancers and psoriasis are 
associated with decreased apoptosis. It seems 
that diseases with increased apoptosis tend to be 
acute, whereas those characterized by decreased 
apoptosis are mostly chronic and associated with 
epidermal hyperplasia or hyperkeratosis (2).
PSORIASIS AnD Bcl-2 fAMIlY 
PROtEInS
 Psoriasis is a common chronic inflammatory 
skin disease characterized by hyperproliferation 
and incomplete differentiation of epidermal kerati-
nocytes (9). Psoriatic keratinocytes possess an en-
hanced ability to resist apoptosis, which might be 
one of the key pathogenetic mechanisms in psori-
asis (10). However, up to now limited data exist re-
garding the underlying mechanisms of this defect 
in the apoptosis control mechanisms of psoriatic 
keratinocytes. As mentioned before, the process 
of apoptosis is controlled by Bcl-2 family proteins 
including several pro-apoptotic and anti-apoptotic 
proteins (11). Data regarding expression of Bcl-2 
family proteins in psoriatic plaques are controver-
sial. Some groups have reported an overexpres-
sion of Bcl-2 protein, whereas others observed 
no expression of anti-apoptotic Bcl-2 molecule in 
psoriatic epidermis (12,13). Takahashi et al. (14) 
found higher expression of Bcl-xL and Bax pro-
teins in psoriatic epidermis, as also reported by 
other authors (15,16). Tomkova et al. observed 
diffuse staining of pro-apoptotic Bax molecule in 
psoriatic lesions, however, along with significant 
overexpression of apoptosis suppressing Bcl-xL 
(15). Therefore, additional studies are necessary 
to determine whether the psoriatic epidermis is in 
a pro-apoptotic or antiapoptotic status regarding 
the expression of Bcl-2 and Bax proteins in psoria-
sis. Data on the expression of anti-apoptotic Bcl-xL 
protein showed its overexpression in all layers of 
psoriatic epidermis (10,14,17). It seems that up-
regulation of Bcl-xL molecule is at least partly re-
sponsible for the increased epidermal thickness, 
a hallmark of psoriasis. Moreover, psoriatic kerati-
nocytes are extremely resistant to apoptosis com-
pared with normal-skin derived keratinocytes (10). 
So, it has been suggested that overexpression of 
Bcl-xL by psoriatic keratinocytes and their resis-
tance to undergo apoptosis finally lead to epider-
mal acanthosis in psoriasis. It has been recently 
shown that tumor necrosis factor-a (TNF-a) stimu-
lates the synthesis of anti-apoptotic Bcl-x and bcl-
2 as well as pro-apoptotic Bax protein in psoriatic 
lesions (12,18). Having in mind the important role 
of TNF-a in psoriatic inflammatory cascade and 
the efficacy of anti-TNF treatment in psoriasis, it 
is likely that TNF-a influences the apoptotic pro-
cess in psoriatic epidermis through changes in the 
intracellular Bax/Bcl-2 ratio. Delayed apoptosis of 
psoriatic keratinocytes and subsequent epidermal 
hyperplasia are partly due to an overexpression 
of keratinocyte-derived IL-15 cytokine and its re-
ceptor IL-15R in psoriatic epidermis (19). Cytokine 
IL-15 is also a potent chemoattractant like T cell 
and NK cell growth factor. It has a role in the influx 
and activation of neutrophils in psoriatic epidermis 
(19). So, it seems that keratinocyte-derived IL-15 
is responsible for prolonged keratinocyte survival 
and also for T cell and neutrophil accumulation in 
psoriatic lesions. 
 The terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick-end labeling (TUNEL) 
method is widely used for the detection of apop-
totic cells (20). Most keratinocytes in psoriatic 
lesions are TUNEL-positive cells, however, with-
out morphological evidence of apoptosis (13,21). 
Moreover, Laporte et al. observed a decreased 
number of apoptotic cells in psoriatic epidermis 
compared to normal one (21). Kawashima et al. 
report an increase of double-strand DNA breaks 
in psoriatic lesions as the result of active DNA 
replication but not apoptosis (17). Therefore, it is 
likely that abundant TUNEL-positive keratinocytes 
in psoriatic epidermis are rather proliferating than 
apoptotic cells. 
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PSORIASIS AnD PERfORIn/gRAnzYME 
OR fas/fasl APOPtOtIC MEChAnISM 
 Psoriasis is nowadays also recognized as a T-
cell mediated disease resulting from aberrant acti-
vation of both innate and adaptive immunity (22). 
The psoriatic inflammatory cascade is orchestrat-
ed by proinflammatory CD4+ T cells producing in-
terferon-γ (Th1 cells) or interleukin-17 (Th17 cells) 
and cytotoxic CD8+ T cells (CTLs) producing Th1 
cytokine pattern. In addition, it is also driven by 
activated keratinocytes that influence T cell activa-
tion and trafficking, as well as by activation of nat-
ural killer (NK) cells and natural killer-like T (NK-T) 
cells representing innate immunity (22). Recently, 
involvement of IL-17 and IL-22 in psoriasis has 
been also recognized. It is likely that the secretion 
of cytokines such as IL-22 and IL-17 could result 
in keratinocyte hyperproliferation, leading to pso-
riatic skin lesions (23). Apart from T-cells, certain 
subsets of dendritic cells (DCs) are found to be im-
portant in the orchestration of the disease process 
(24). Proinflammatory CD11c+ DCs, which pro-
duce TNF-α, are increased in psoriasis, whereas 
Langerhans cells from symptomless psoriatic skin 
show migratory defects (24-26). Moreover, psori-
atic dermal DCs promote increased proliferation 
of autoreactive T cells and production of Th1 cyto-
kines, IFN-γ and IL-2.
 The role of cell cytotoxicity mediated by cyto-
toxic CD8+ T cells and NK cells in psoriasis is as 
yet unclear. CTLs and NK cells mediate apopto-
sis via the release of cell granules, perforin and 
granzymes, or by binding of ligands to their death 
receptors on target cells (27). Upon activation, 
CTLs and NK cells release perforin, a pore form-
ing molecule, which enables entry of granzyme 
into the target cell in order to mediate DNA degra-
dation (28). The importance of perforin-mediated 
cytotoxicity has been demonstrated in several 
autoimmune diseases and in some inflammatory 
skin diseases as well (29,30). We have previ-
ously reported on the systemic up-regulation of 
perforin molecule in the exacerbation phase of 
psoriasis that were mainly related to perforin-posi-
tive CD8+P+ cells, a subpopulation with cytotoxic 
potential and rapid killing cells (31). A similar situ-
ation was found in psoriatic lesions where we ob-
served significant accumulation of perforin-posi-
tive cells in suprabasal epidermis in close contact 
with damaged keratinocytes (32). Yawalkar et al. 
also report on up-regulation of perforin and gran-
zyme-B expression in psoriatic lesions (33). It is 
likely that perforin-positive T cells induce damage 
to adjacent keratinocytes subsequently triggering 
an injury response program and regenerative hy-
perplasia, a type of hyperplasia programmed in 
keratinocytes as an injury-repair response path-
way (34,35). In addition to the established role for 
perforin as an effector molecule, it may also act as 
a regulatory molecule of the immune system (36). 
In the skin, CTLs might use perforin molecule to 
regulate antigen presentation by antigen present-
ing cells, which could result in persistence of the 
chronic immune system activation (36). 
 Apoptosis induced by CTLs may also be me-
diated by the Fas ligand (FasL) binding to Fas 
(CD95) on target cell (37). In addition, Fas expres-
sion on keratinocytes can be up-regulated by Th1 
type cytokines that create a microenvironment typ-
ical for psoriasis (38). Several groups have report-
ed overexpression of Fas in psoriatic epidermis, 
so it is likely that Th1 cytokines up-regulate Fas 
expression in psoriatic lesions (14). Data on FasL 
expression in psoriatic skin are controversial, as 
some groups report low FasL expression and the 
others observed an increase of FasL in all cell lay-
ers of psoriatic epidermis (39,40). However, it has 
been recently suggested that Fas/FasL signaling 
might induce an alternative pathway promoting the 
synthesis of inflammatory cytokines, TNF-a and 
IL-8 instead of apoptosis (41). Assuming the fact 
that psoriatic keratinocytes are relatively resistant 
to apoptosis, it is likely that elevated expression 
of Fas along with anti-apoptotic Bcl-xL protein in 
psoriatic epidermis inhibit Fas-mediated apoptosis 
and induce proinflammatory TNF-a production by 
keratinocytes. Moreover, it is likely that Fas/FasL 
pathway is an essential early event in psoriasis in-
duction (41).
 In conclusion, all these findings clearly show the 
importance of apoptotic process in the develop-
ment and maintenance of psoriatic lesions. Based 
on these observations, novel apoptosis-based 
therapies could be directed towards enhancement 
of apoptotic process in psoriasis.
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